Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, Daste A, Koralewski P, Zurawski B, Taberna M, Saba NF, Mak M, Kawecki A, Girotto G, Alvarez Avitia MA, Even C, Toledo JGR, Guminski A, Müller-Richter U, Kiyota N, Roberts M, Khan TA, Miller-Moslin K, Wei L, Argiris A. Haddad RI, et al. Among authors: daste a. J Clin Oncol. 2023 Apr 20;41(12):2166-2180. doi: 10.1200/JCO.22.00332. Epub 2022 Dec 6. J Clin Oncol. 2023. PMID: 36473143 Free PMC article. Clinical Trial.
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J. Siu LL, et al. Among authors: daste a. JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628. JAMA Oncol. 2019. PMID: 30383184 Free PMC article. Clinical Trial.
Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Saleh K, Daste A, Martin N, Pons-Tostivint E, Auperin A, Herrera-Gomez RG, Baste-Rotllan N, Bidault F, Guigay J, Le Tourneau C, Saada-Bouzid E, Even C. Saleh K, et al. Among authors: daste a. Eur J Cancer. 2019 Nov;121:123-129. doi: 10.1016/j.ejca.2019.08.026. Epub 2019 Sep 28. Eur J Cancer. 2019. PMID: 31574417
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, Clement PM, Mesia R, Kutukova S, Zholudeva L, Daste A, Caballero-Daroqui J, Keam B, Vynnychenko I, Lafond C, Shetty J, Mann H, Fan J, Wildsmith S, Morsli N, Fayette J, Licitra L. Ferris RL, et al. Among authors: daste a. Ann Oncol. 2020 Jul;31(7):942-950. doi: 10.1016/j.annonc.2020.04.001. Epub 2020 Apr 12. Ann Oncol. 2020. PMID: 32294530 Free article. Clinical Trial.
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Chevalier T, Daste A, Saada-Bouzid E, Loundou A, Peyraud F, Lambert T, Le Tourneau C, Peyrade F, Dupuis C, Alfonsi M, Fayette J, Reure J, Huguet F, Fakhry N, Toullec C, Salas S. Chevalier T, et al. Among authors: daste a. Cancer Med. 2021 Jun;10(12):3952-3963. doi: 10.1002/cam4.3953. Epub 2021 May 25. Cancer Med. 2021. PMID: 34080776 Free PMC article.
Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors.
Tran BT, Gelin A, Durand S, Texier M, Daste A, Toullec C, Benihoud K, Breuskin I, Gorphe P, Garic F, Brenner C, Le Tourneau C, Fayette J, Niki T, David M, Busson P, Even C. Tran BT, et al. Among authors: daste a. Oncoimmunology. 2022 Dec 17;12(1):2150472. doi: 10.1080/2162402X.2022.2150472. eCollection 2023. Oncoimmunology. 2022. PMID: 36545254 Free PMC article.
Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study.
Vienne A, Collet L, Chevalier T, Borel C, Tardy M, Huguet F, Richard S, Salas S, Saada-Bouzid E, Fayette J, Daste A. Vienne A, et al. Among authors: daste a. BMC Cancer. 2023 Jul 14;23(1):663. doi: 10.1186/s12885-023-11133-5. BMC Cancer. 2023. PMID: 37452287 Free PMC article.
Atezolizumab for the treatment of renal cell carcinoma.
Lafon M, Domblides C, Daste A, Sionneau B, Ravaud A, Bernhard JC, Gross-Goupil M. Lafon M, et al. Among authors: daste a. Expert Opin Biol Ther. 2020 Jul;20(7):679-686. doi: 10.1080/14712598.2020.1751113. Epub 2020 Apr 13. Expert Opin Biol Ther. 2020. PMID: 32245328
56 results